Valine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Valine: From Essential Amino Acid Supplementation to Sclerosing Cholangitis
One-Sentence Summary
Valine is a branched-chain essential amino acid; no approved therapeutic indication or mechanism-of-action data is on file for this candidate. The TxGNN model predicts a possible association with Sclerosing Cholangitis, but this is currently supported only by 0 clinical trials and 2 observational/genetic-association publications, neither of which tests valine as an intervention.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established — Valine is an essential branched-chain amino acid; no approved therapeutic indication is recorded in this evidence pack |
| Predicted New Indication | Sclerosing Cholangitis |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L4 (mechanistic/association studies only, no interventional or clinical data) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for valine is not available in this evidence pack. Based on known biology, valine is one of the branched-chain amino acids (BCAAs) involved in general protein and energy metabolism; it has no established disease-specific therapeutic indication, so there is no original-indication-to-new-indication pharmacological bridge to evaluate here.
The literature supporting the sclerosing cholangitis prediction is indirect: a Mendelian randomization study (PMID 39015781) found that certain blood metabolites show causal association signals with cholestatic liver disease risk, but it does not specifically implicate valine as a treatment target. A second, older study (PMID 15790420) examined plasma tyrosine — not valine — in relation to fatigue in primary biliary cirrhosis/primary sclerosing cholangitis patients, making its direct relevance to valine limited.
Important caveat on the wider prediction batch: among the remaining 9 TxGNN-predicted indications for this candidate, the majority (angle-closure glaucoma, hyperthyroidism, resistance to thyroid hormone, hyperthyroxinemia, etc.) are flagged by the evidence pack itself as likely false positives arising from nomenclature collision — “Val” is a standard three-letter abbreviation for valine used throughout gene-mutation nomenclature (e.g., V336M, L346V, Val109), and is also a name-fragment match with the unrelated drug valsartan. None of these represent a genuine pharmacological rationale. This substantially lowers confidence in the overall prediction set for this drug and reinforces caution specifically for the top-ranked candidate as well, since it emerged from the same low-specificity signal environment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39015781 | 2024 | Mendelian Randomization | Frontiers in Medicine | Investigated causal relationships between blood metabolites/metabolic pathways and cholestatic liver diseases (PBC/PSC); did not specifically identify valine as a causal or therapeutic factor |
| 15790420 | 2005 | Observational/Correlation | BMC Gastroenterology | Examined plasma tyrosine (not valine) concentration in relation to fatigue in PBC/PSC patients; abnormal amino acid patterns noted but no valine-specific intervention data |
South Africa Market Information
Valine (DB00161) has no SAHPRA registrations on file and is not currently marketed in South Africa (0 licenses recorded).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: this candidate carries a Blocking data gap — TFDA/PI-equivalent warning and contraindication data are not currently available, which by itself prevents progression to an initial (S1) safety assessment regardless of efficacy evidence.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (sclerosing cholangitis) is supported only by indirect metabolomic association data (L4, no clinical trials, no interventional studies), and a Blocking data gap on safety/label information prevents any safety pre-assessment. In addition, most of the other 9 TxGNN-predicted indications for this drug are attributable to “Val” nomenclature collisions rather than genuine pharmacology, which lowers overall confidence in this prediction batch.
To proceed, the following is needed:
- TFDA/SAHPRA-equivalent label data: warnings, contraindications, and drug interactions (currently Blocking gap, DG001)
- Confirmed mechanism of action (MOA) data for valine (currently High-severity gap, DG002)
- Interventional (not purely observational/genetic) evidence directly testing valine supplementation in cholestatic/sclerosing cholangitis populations
- Clarification of any established original indication, since none is currently on file
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.